Preclinical Study Results Of Merrimack Pharmaceuticals Inc. (MACK)'s MM-141 Published In Molecular Cancer Therapeutics
2/18/2014 9:02:52 AM
CAMBRIDGE, Mass., Feb. 18, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the manuscript "MM-141, an IGF-1R- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-1R Inhibitors" has been published in Molecular Cancer Therapeutics and selected for the Highlights section in the current issue (Volume 13, Issue 2).
Help employers find you! Check out all the jobs and post your resume.
comments powered by